Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tonika Bohnert

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 8, 2016
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry PerspectiveTonika Bohnert, Aarti Patel, Ian Templeton, et al.
Drug Discovery Today|May 7, 2017
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspectiveHarvey Wong, Tonika Bohnert, Valeriu Damian-Iordache, et al.
Journal of Medicinal Chemistry|July 23, 2020
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune DiseasesBin Ma, Tonika Bohnert, Kevin L Otipoby, et al.
The AAPS Journal|January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscapeEdgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2022
Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse modelGeorge H Vandeveer, Robert M Arduini, Darren P Baker, et al.
Bioorganic & Medicinal Chemistry|May 30, 2019
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screensBrian T Hopkins, Eris Bame, Noah Bell, et al.
Journal of Medicinal Chemistry|April 7, 2026
Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for NeuroinflammationBrian T Hopkins, Isaac E Marx, Harlod George Vandeveer, et al.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
Journal of Medicinal Chemistry|November 4, 2021
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple SclerosisBrian T Hopkins, Eris Bame, Bekim Bajrami, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 8, 2016
Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry PerspectiveTonika Bohnert, Aarti Patel, Ian Templeton, et al.
Drug Discovery Today|May 7, 2017
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspectiveHarvey Wong, Tonika Bohnert, Valeriu Damian-Iordache, et al.
Journal of Medicinal Chemistry|July 23, 2020
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune DiseasesBin Ma, Tonika Bohnert, Kevin L Otipoby, et al.
The AAPS Journal|January 30, 2015
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscapeEdgar Schuck, Tonika Bohnert, Arijit Chakravarty, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2022
Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse modelGeorge H Vandeveer, Robert M Arduini, Darren P Baker, et al.
Bioorganic & Medicinal Chemistry|May 30, 2019
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screensBrian T Hopkins, Eris Bame, Noah Bell, et al.
Journal of Medicinal Chemistry|April 7, 2026
Leveraging Kinase Drugs for Neurosciences: Discovery of Selective, CNS-Penetrant Reversible Bruton's Tyrosine Kinase Inhibitors as Therapeutics for NeuroinflammationBrian T Hopkins, Isaac E Marx, Harlod George Vandeveer, et al.
Bioorganic & Medicinal Chemistry|July 27, 2021
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitorsBrian T Hopkins, Eris Bame, Noah Bell, et al.
Journal of Medicinal Chemistry|November 4, 2021
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple SclerosisBrian T Hopkins, Eris Bame, Bekim Bajrami, et al.
Pageof 2